The role of asymmetric dimethylarginine (ADMA) and leptin in hypertensive patients

Journal of International Medical Research

Volumn 36, Issue 1, 2008, Pages 54-62

  Atamer, Aytaç ^a   Ilhan, N ^b   Kocyigit, Y ^c   Toprak, G ^c   Ozbay, M ^a   Celik, Y ^c  

^a Diyarbakir Devlet Hastanesi   (Turkey)

^b FIRAT UNIVERSITY   (Turkey)

^c DICLE UNIVERSITY   (Turkey)

Author keywords

Asymmetric dimethylarginine (ADMA); Hypertension; Insulin resistance; Leptin; Lipoproteins; Malondialdehyde (MDA)

Indexed keywords

HIGH DENSITY LIPOPROTEIN; HOMOCYSTEINE; INSULIN; LEPTIN; LOW DENSITY LIPOPROTEIN; MALONALDEHYDE; N(G),N(G) DIMETHYLARGININE; SOMATOMEDIN BINDING PROTEIN 3; SOMATOMEDIN C; TRIACYLGLYCEROL;

ADULT; AGED; AMINO ACID BLOOD LEVEL; ARTICLE; ATHEROSCLEROSIS; CARDIOVASCULAR FUNCTION; CARDIOVASCULAR RISK; CHOLESTEROL BLOOD LEVEL; CLINICAL ARTICLE; FEMALE; GLUCOSE BLOOD LEVEL; HUMAN; HYPERHOMOCYSTEINEMIA; HYPERINSULINEMIA; HYPERLEPTINEMIA; HYPERTENSION; INSULIN BLOOD LEVEL; INSULIN RESISTANCE; LIPID BLOOD LEVEL; LIPID METABOLISM; LIPID PEROXIDATION; LIPOPROTEIN BLOOD LEVEL; MALE; METABOLIC PARAMETERS; METABOLIC REGULATION; OXIDATIVE STRESS; PATHOGENESIS; PROTEIN BLOOD LEVEL; PROTEIN FUNCTION; RISK FACTOR; TRIACYLGLYCEROL BLOOD LEVEL;

EID: 39149096877     PISSN: 03000605     EISSN: None     Source Type: Journal    
DOI: 10.1177/147323000803600108     Document Type: Article

References (31)

1. Takiuchi S, Fujii H, Kamide K, et al: Plasma asymmetric dimethylarginine and coronary and peripheral endothelial dysfunction in hypertensive patients. Am J Hypertens 2004; 17: 802-808.
2. Sabuncu T, Vural H, Harma M, et al: Oxidative stress in polycystic ovary syndrome and its contribution to the risk of cardiovascular disease. Clin Biochem 2001; 34: 407-413.
3. Napoli C, Sica V, de Nigris F, et al: Sulfydryl angiotensin-converting enzyme inhibition induces sustained reduction of systemic oxidative stress and improves the nitric oxide pathway in patients with essential hypertension. Am Heart J 2004; 148: e5.
4. Sydow K, Schwedhelm E, Arakawa N, et al: ADMA and oxidative stress are responsible for endothelial dysfunction in hyperhomocyst(e)inemia: effects of L-arginine and B vitamins. Cardiovasc Res 2003; 57: 244-252.
5. Stühlinger MC, Abasi F, Chu JW, et al: Relationship between insulin resistance and an endogenous nitric oxide synthase inhibitor. JAMA 2002; 287: 1420-1426.
6. Lentz SR, Rodionov RN, Dayal S: Hyperhomocysteinemia, endothelial dysfunction, and cardiovascular risk: the potential role of ADMA. Atherosclerosis 2003; 4(suppl): 61-65.
7. Golderisi M, Tagliamonte, D'Errico A: Independent association of plasma leptin levels and left ventricular isovolemic relaxation in uncomplicated hypertension. Am J Hypertens 2001; 14: 1019-1024.
8. Suter PM, Locher R, Hasler E, et al: Is there a role for the ob gene product leptin in essential hypertension. Am J Hypertens 1998; 11: 1305-1311.
9. Watanabe T, Itokawa M, Nakagawa Y, et al: Increased levels of insulin-like growth factor binding protein-3 in hypertensive patients with carotid atherosclerosis. Am J Hypertens 2003; 16: 754-760.
10. Verdecchia P, Reboldi G, Schillaci G: Circulating insulin and insulin growth factor-1 are independent determinants of left ventricular mass and geometry in essential hypertension. Circulation 1999; 100: 1802-1807.
11. The Joint National Committee on Detection, Evaluation and Treatment of High Blood Pressure: The Sixth Report of the Joint National Committee on Detection, Evaluation and Treatment of High Blood Pressure (JNC-VI). Arch Intern Med 1997; 157: 2413-2446.
12. G-dimethylarginine in human plasma by high performance liquid chromatography. J Chromatogr B Biomed Sci Appl 1997; 692: 467-471.
13. Araki A, Sako Y: Determination of free and total homocysteine in human plasma by high performance liquid chromatography with fluorescence detection. J Chromatogr 1987; 422: 43-52.
14. Asakawa T, Matsushita S: Coloring conditions of thiobarbituric acid test for detecting lipid hydroperoxides. Lipids 1980; 15: 137-140.
15. Haffner SM, Miettinen H, Stern MP: The homeostasis model in the San Antonio Heart Study. Diabetes Care 1997; 20: 1087-1092.
16. Schulze F, Lenzen H, Hanefeld C, et al: Asymmetric dimethylarginine is an independent risk factor for coronary heart disease: results from the multicenter Coronary Artery Risk Determination investigating the Influence of ADMA Concentration (CARDIAC) study. Am Heart J 2006; 152: 493.e1-493.e8.
17. Kielstein J, Tsikas D, Fliser D: Effects of asymmetric dimethylarginine (ADMA) infusion in humans. Eur J Clin Pharmacol 2006; 62: 39-44.
18. Wang J, Sim AS, Wang XL, et al: Relation between plasma asymmetric dimethylarginine (ADMA) and risk factors for coronary disease. Atherosclerosis 2006; 184: 383-388.
19. Matsuoka H, Itoh S, Kimoto M, et al: Asymmetrical dimethylarginine, an endogenous nitric oxide synthose inhibitor, in experimental hypertension. Hypertension 1997; 29: 242-247.
20. Korandji C, Zeller M, Guilland JC, et al: Asymmetric dimethylarginine (ADMA) and hyperhomocysteinemia in patients with acute myocardial infarction. Clin Biochem 2007; 40: 66-72.
21. Böger RH: Asymmetric dimethylarginine (ADMA) and cardiovascular disease: insights from prospective clinical trials. Vasc Med 2005; 10: S19-S25.
22. Boger RH, Lentz SR, Bode-Boger SM, et al: Elevation of asymmetrical dimethylarginine may mediate endothelial dysfunction during experimental hyperhomocyst(e)inaemia in humans. Clin Sci (Lond) 2001; 100: 161-167.
23. Schmitt B, Wolters M, Kressel G, et al: Effects of combined supplementation with B vitamins and antioxidants on plasma levels of asymmetric dimethylarginine (ADMA) in subjects with elevated risk for cardiovascular disease. Atherosclerosis 2007; 193: 168-176.
24. Tsioufis C, Antoniadis D, Stefanadis C, et al: Relationships between new risk factors and circadian blood pressure variation in untreated subjects with essential hypertension. Am J Hypertens 2002; 15: 600-604.
25. Ledwozyw A, Michalak J, Stepien A, et al: The relationship between plasma triglycerides, cholesterol, total lipids and lipid peroxidation products during human atherosclerosis. Clin Chim Acta 1986; 155: 275-283.
26. Srinivas K, Bhaskar MV, Kumari RA, et al: Antioxidonts, lipid peroxidation, and lipoproteins in primary hypertension. Indian Heart J 2000; 52: 285-288.
27. Kanani PM, Sinkey CA, Browning RL, et al: Role of oxidant stress in endothelial dysfunction produced by experimental hyperhomocyst(e)inemia in humans. Circulation 1999; 100: 1161-1168.
28. Sydow K, Münzel T: ADMA and oxidative stress. Atherosclerosis 2003; 4(suppl): 41-51.
29. Asakawa H, Tokunaga K, Kamakami F: Relationship of leptin level with metabolic disorders and hypertension in Japanese type 2 diabetes mellitus. J Diabetes Complications 2001; 15: 57-62.
30. Chan NN, Chan CN: Asymmetric dimethylarginine (ADMA): a potential link between endothelial dysfunction and cardiovascular diseases in insulin resistance syndrome? Diabetologia 2002; 45: 1609-1616.
31. Juul A, Scheike T, Davidsen M, et al: Low serum insulin-like growth factor I is associated with increased risk of ischemic heart disease: a population-based case-control study. Circulation 2002; 106: 939-944.